Eintrag weiter verarbeiten
Clinical utility of C‐terminal telopeptide of type 1 collagen in multiple myeloma
Gespeichert in:
Personen und Körperschaften: | , , , , , , , , , , , , , |
---|---|
Titel: |
Clinical utility of C‐terminal telopeptide of type 1 collagen in multiple myeloma |
In: | British Journal of Haematology, 173, 2016, 1, S. 82-88 |
veröffentlicht: |
Wiley
|
Umfang: | 82-88 |
ISSN: |
1365-2141 0007-1048 |
DOI: | 10.1111/bjh.13928 |
Zusammenfassung: | <jats:title>Summary</jats:title><jats:p>Myeloma bone disease (<jats:styled-content style="fixed-case">MBD</jats:styled-content>) is a major cause of morbidity in multiple myeloma (<jats:styled-content style="fixed-case">MM</jats:styled-content>). We investigated bone turnover markers (BTM) as relapse predictors and biomarkers for monitoring <jats:styled-content style="fixed-case">MBD</jats:styled-content>. We measured C‐terminal telopeptide of type I collagen (<jats:styled-content style="fixed-case">CTX</jats:styled-content>‐1), and Procollagen type 1 N Propeptide (P1<jats:styled-content style="fixed-case">NP</jats:styled-content>) in 86 <jats:styled-content style="fixed-case">MM</jats:styled-content> patients and 26 controls. <jats:styled-content style="fixed-case">CTX</jats:styled-content>‐1 was higher in newly diagnosed patients compared to control, remission and relapse (<jats:italic>P</jats:italic> < 0·05), and decreased following treatment. In the setting of relapse, a <jats:styled-content style="fixed-case">CTX</jats:styled-content>‐1 rise greater than the calculated least significant change (<jats:styled-content style="fixed-case">LSC</jats:styled-content>) was observed in 26% of patients 3–6 months prior to relapse (<jats:italic>P</jats:italic> = 0·007), and in 60·8% up to 3 months before relapse (<jats:italic>P</jats:italic> = 0·015). Statistically significant changes in <jats:styled-content style="fixed-case">CTX</jats:styled-content>‐1 levels were also observed in patients who were with and without bisphosphonate therapy at the time of relapse. In patients with normal renal function, mean <jats:styled-content style="fixed-case">CTX</jats:styled-content>‐1 level was highest in the newly diagnosed group (0·771 ± 0·400 μg/l), and lowest in the remission group (0·099 ± 0·070 μg/l) (<jats:italic>P</jats:italic> < 0·0001). P1<jats:styled-content style="fixed-case">NP</jats:styled-content> levels were not statistically different across the patient groups. We conclude that <jats:styled-content style="fixed-case">CTX</jats:styled-content>‐1, measured on an automated hospital laboratory platform, has a role in routine treatment monitoring and predicting relapse of <jats:styled-content style="fixed-case">MBD</jats:styled-content>, even in patients on bisphosphonates.</jats:p> |
Format: | E-Article |
Quelle: | Wiley (CrossRef) |
Sprache: | Englisch |